Atreca to Present at the 37th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jan 2, 2019--Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced today that John A. Orwin, President and Chief Executive Officer, will present at the 37 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019, at 1:30 p.m. Pacific Standard Time in San Francisco, CA.
About Atreca, Inc.
Atreca is a privately held biotechnology company developing novel therapeutics based on a deep understanding of the human immune response. We focus in a unique way on the immune responses of patients in therapeutic areas where such responses are the key phenomenon driving clinical outcomes, enabling us to discover and develop novel immunotherapies. Atreca is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications, thus driving better therapeutic outcomes. For more information on Atreca, please visit www.atreca.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190102005590/en/
CONTACT: Atreca, Inc.
EVP and Chief Financial Officer
Nancie Steinberg, 212-213-0006, ext. 318
email@example.comRobert Flamm, 212-213-0006, ext. 364
Alex Gray, 212-213-0006, ext. 355
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL
SOURCE: Atreca, Inc.
Copyright Business Wire 2019.
PUB: 01/02/2019 04:05 PM/DISC: 01/02/2019 04:05 PM